Angels Santé

MB Therapeutics is a pharmaceutical company specializing in personalized medicine. It offers a patient-centric system for developing and producing customized medications, including evaluation services. The company excels in tailoring medication dosage, forms, and combining multiple active ingredients into a single unit, enabling healthcare professionals to enhance treatment precision and improve patient adherence.

Sirius NeoSight is a biotechnology and pharmaceutical company focused on the early detection and treatment of subclinical neo-cancers. It develops healthcare technology software that serves clients in the healthcare sector, utilizing patented technology to measure the fluidity of membranes specifically in oncology. This innovative approach enables the detection and purification of Circulating Tumor Cells, contributing to advancements in personalized medicine. Through its unique offerings, Sirius NeoSight aims to improve cancer diagnostics and therapeutic strategies, ultimately enhancing patient care and outcomes in oncology.

Hephaistos Pharma is a biotechnology firm dedicated to advancing oncology treatments through innovative immunotherapy solutions. The company focuses on developing next-generation therapies that utilize active and non-specific immuno-stimulants, which enhance the efficacy of existing antibodies and transform cold tumors into hot targets for the immune system. By addressing unmet medical needs, Hephaistos Pharma aims to provide effective treatment options for patients with incurable cancers. Their platform is designed to stimulate immune responses, thereby improving the overall efficiency of immunotherapy. The firm also offers an online inquiry form on its website for further engagement.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Abcely is a biotechnology company focused on developing innovative treatments for mucosal cancers, specifically through a novel anti-cancer medication. The firm specializes in medical and pharmaceutical technologies that employ a new approach to immunotherapy. This approach utilizes active therapeutic molecules derived from biological compounds, which are identified as potential active ingredients. Abcely aims to demonstrate the efficacy of these compounds in clinical settings, thereby providing healthcare professionals with more effective options for cancer treatment.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Ensweet is a telemedicine platform specializing in telerehabilitation services aimed at enhancing patient accessibility to rehabilitation care. The company provides a range of equipment, including heart rate sensors and physical activity tools, allowing patients to engage in exercise regardless of their circumstances. This innovative approach ensures that rehabilitation is accessible to all, promoting healthier lifestyles and improved recovery outcomes for individuals in need of rehabilitation services.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women through innovative regenerative medicine techniques. The company specializes in creating bioprostheses using 3D bioprinting technology, offering an alternative to traditional breast reconstruction methods. By focusing on natural products, Healshape aims to provide women with long-lasting, aesthetically pleasing results, helping them regain their self-confidence following surgery.

Vaxxel is a biotechnology company focused on developing innovative live-attenuated vaccine candidates aimed at preventing critical respiratory diseases, particularly bronchiolitis and pneumonia caused by viral infections. The company specializes in creating novel vaccines targeting human metapneumovirus and other respiratory viruses. By leveraging its proprietary platform, Vaxxel aims to enhance the healthcare industry's ability to combat these significant health threats, ultimately improving patient outcomes and addressing unmet medical needs in the field of respiratory diseases.

Mapatho is a company that has created an online medical directory and search platform aimed at helping patients locate free medical and paramedical experts. The platform is specifically designed to assist individuals with chronic illnesses by providing a comprehensive directory organized by chronic pathology. This structure helps to reduce the post-diagnosis confusion often experienced by patients, as it facilitates the identification of health professionals who collaborate within shared ecosystems. By fostering a sense of solidarity among patients, Mapatho enables those dealing with chronic diseases to connect with available pathology experts more effectively.

Gaoma Therapeutics is a biotechnology company dedicated to developing therapeutic molecules aimed at addressing unmet medical needs in neurological and inflammatory diseases. With a specific focus on epilepsy and cognitive disorders, the company is advancing its initial medicine candidate, GAO-3-02, which is a proprietary active component. Gaoma Therapeutics is committed to exploring the potential applications of its innovative lipid derivatives beyond its core specialties, seeking to expand its portfolio of drug candidates and provide essential treatments for healthcare organizations and their patients.

OncoDiag is a biotechnology company based in Normandy, France, specializing in the development of non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, Urotest, is a urine test designed for the diagnosis and monitoring of bladder cancer. Additionally, the company is advancing its pipeline with Colodiag, which focuses on the early detection of colorectal cancer. OncoDiag's portfolio also includes a tissue-based test for predicting non-evolutive localized prostate cancer. By offering these innovative diagnostic solutions, OncoDiag aims to enhance the capabilities of healthcare professionals in cancer diagnosis and management.

Omini is a biotechnology company based in Saint Mandé, France, founded in 2019. It specializes in the development of portable and multipurpose bio-sensing devices designed for immediate blood testing. Omini's biosensor platform enables the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to customize therapies and prevent acute crises in patients with chronic conditions. By leveraging multiplex electrochemical biosensor technology, the company offers affordable and accurate monitoring solutions that facilitate decentralized testing and at-home monitoring, ultimately helping to alleviate the burden on healthcare systems. Omini primarily serves general practitioners, aiming to enhance patient care through innovative diagnostic tools.

Braintale is a Paris-based company founded in 2018 that specializes in developing and distributing innovative diagnostic and prognostic tools specifically for brain-injured patients. The company's digital medical care platform is designed for hospitals to effectively analyze MRI reports, providing accessible solutions that meet the needs of healthcare professionals and patients alike. Braintale’s products are grounded in over 15 years of clinical development, focusing on predicting patient outcomes, particularly for those in comas due to severe traumatic brain injuries, cardiac arrests, or hemorrhagic strokes. By facilitating easier diagnoses, Braintale aims to enhance patient care in critical settings, ultimately improving the prognosis for individuals with severe brain injuries.

GoSense is a company that specializes in developing innovative sensory enhancement technologies aimed at improving the mobility and independence of visually impaired individuals. The company has created solutions that include a sound-based GPS and travel assistant, which utilizes spatialized sound to help users navigate their environment. Additionally, GoSense offers a smart sensory device designed to detect obstacles, reducing the risk of injury while traveling. Their products also feature outside-the-ear headphones that allow users to remain aware of their surroundings, promoting safe travel without reliance on others. Through these advancements, GoSense aims to augment human perception and empower visually impaired persons to navigate their world more confidently.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Hillo is a company based in Palaiseau, France, founded in 2016, that specializes in the design and development of an artificial intelligence platform aimed at transforming the lives of diabetic patients. It creates tools for continuous blood glucose monitoring, offering a diabetes management platform that provides real-time glycemia predictions and personalized treatment suggestions. The software is designed to adapt to individual patients, synchronizing with insulin delivery devices, logging treatment history, assessing meal intake, and learning from behavioral and physiological responses. Through these innovations, Hillo aims to enhance diabetes management and improve health outcomes for patients.

Primaa is a MedTech company that specializes in the development of an artificial intelligence-based platform for automated and accurate cancer diagnosis. The company’s software utilizes advanced image analysis and deep learning techniques to enhance the detection of major cancer biomarkers, thereby facilitating the identification of tissue damage and supporting personalized treatment plans. By digitizing histological slides and utilizing a comprehensive image database, Primaa's technology allows for a greater number of reliable cancer diagnoses, which improves clinical outcomes in oncology.

Wefight Inc. is a technology company focused on enhancing patient care within the healthcare sector. Founded in 2017 and based in Montpellier, France, the company has developed a virtual medical assistance platform, including an application called Vik-Sein, which specifically targets breast cancer patients. The application provides vital support by answering patient inquiries, sending reminders for medication adherence, and facilitating the discovery of relevant clinical trials. Additionally, Wefight's platform enables patients to monitor side effects and share health data with their healthcare providers, thereby improving the overall patient experience and enabling clinicians to better understand and manage patients' conditions between visits. By providing these services, Wefight aims to empower patients to manage their health from home while optimizing the time and effectiveness of care teams.

SentinHealth is a life science company specializing in integrated care solutions designed to monitor and prevent the deterioration of chronic illnesses, particularly heart failure. The company develops advanced telemonitoring technology that includes an implant connected to the cloud, providing daily health status updates and predictive insights. This system focuses on early detection of acute decompensated heart failure (ADHF) by monitoring daily heart activity and other indicators from the digestive system, allowing for timely interventions before hospitalization becomes necessary. SentinHealth addresses the critical needs of patients requiring continuous automated monitoring, ultimately aiming to enhance patient outcomes in the management of serious chronic conditions.

OncoDiag is a biotechnology company based in Normandy, France, specializing in the development of non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, Urotest, is a urine test designed for the diagnosis and monitoring of bladder cancer. Additionally, the company is advancing its pipeline with Colodiag, which focuses on the early detection of colorectal cancer. OncoDiag's portfolio also includes a tissue-based test for predicting non-evolutive localized prostate cancer. By offering these innovative diagnostic solutions, OncoDiag aims to enhance the capabilities of healthcare professionals in cancer diagnosis and management.

C4Diagnostics is a developer of in vitro diagnostic (IVD) kits that leverages proprietary technology to enhance the speed and sensitivity of diagnostic testing. The company focuses on creating medical devices and equipment that streamline the screening process for urinary tract infections, allowing for the reliable detection, counting, and concentration of relevant microorganisms in clinical microbiology. By enabling hospitals and laboratories to conduct culture-based IVD tests and specific fluorescence assessments, C4Diagnostics contributes to more efficient and effective diagnostic practices in healthcare settings.

Cardiawave is a medical technology company established in 2014 through a collaboration between the Langevin Institute, renowned for its expertise in ultrasound imaging and therapy, and the Georges Pompidou European Hospital, which specializes in valve disease and cardiac ultrasound imaging. The company focuses on developing a non-invasive ultrasonic device aimed at treating heart valve diseases, particularly calcified aortic stenosis. This innovative device employs real-time image guidance and ultrasound technology to provide effective treatment without causing thermal injury, facilitating quicker procedures and enhancing the likelihood of successful outcomes for patients. With an experienced management team, Cardiawave has raised over €14 million to advance its product development and conduct preclinical studies, with the goal of initiating first-in-man trials.

PREMEDIT SAS is a company based in Loos, France, that specializes in the design and development of application software under the brand name Running Care. This software is aimed at runners, providing tools to predict, prevent, and manage pain and injuries through the use of artificial intelligence to monitor their health. Running Care is classified as a class I medical device for the diagnosis and rehabilitation of running-related injuries and carries the CE marking, indicating compliance with health regulations. In addition to its core functionalities, the software offers features such as integration with other running apps, affiliation with sports and healthcare products, a content platform for non-healthcare professionals, sports medicine data analysis, and promotional activities related to sports and health issues. Founded in 2016, PREMEDIT is committed to enhancing the well-being of runners through innovative technological solutions.

Hillo is a company based in Palaiseau, France, founded in 2016, that specializes in the design and development of an artificial intelligence platform aimed at transforming the lives of diabetic patients. It creates tools for continuous blood glucose monitoring, offering a diabetes management platform that provides real-time glycemia predictions and personalized treatment suggestions. The software is designed to adapt to individual patients, synchronizing with insulin delivery devices, logging treatment history, assessing meal intake, and learning from behavioral and physiological responses. Through these innovations, Hillo aims to enhance diabetes management and improve health outcomes for patients.

Auxivia, established in 2015 and headquartered in Paris, France, specializes in designing and developing smart glasses connected to an online platform. These glasses, indistinguishable from regular ones, track water intake and alert users to prevent dehydration. The company's innovative solution aims to enhance caregiving quality for elderly individuals, particularly those with declining autonomy, by enabling caregivers to monitor and manage their water intake effectively.

Cypheme is a company that specializes in counterfeit detection through its innovative application, which leverages artificial intelligence and machine learning. The application enables users to identify counterfeit products by analyzing the micro-structure of product packaging using only a smartphone camera. By employing advanced pattern recognition techniques, Cypheme's technology allows consumers to verify the authenticity of various products easily and efficiently. This approach not only helps in combating counterfeit goods but also enhances consumer trust in product quality and safety.

Cardiawave is a medical technology company established in 2014 through a collaboration between the Langevin Institute, renowned for its expertise in ultrasound imaging and therapy, and the Georges Pompidou European Hospital, which specializes in valve disease and cardiac ultrasound imaging. The company focuses on developing a non-invasive ultrasonic device aimed at treating heart valve diseases, particularly calcified aortic stenosis. This innovative device employs real-time image guidance and ultrasound technology to provide effective treatment without causing thermal injury, facilitating quicker procedures and enhancing the likelihood of successful outcomes for patients. With an experienced management team, Cardiawave has raised over €14 million to advance its product development and conduct preclinical studies, with the goal of initiating first-in-man trials.

BibeliB is a brand of smart and trendy travel accessories. They created the first smart suit case. This suitcase bag is equipped with e an integrated traceability and insurance system. Thanks to our My BibeliB Paris app your suitcase cover is now connected to geolocate your suitcase and activate it more easily.

Medicapp Connect S.A.S. is a company based in Paris, France, that specializes in designing and developing healthcare software solutions. Founded in 2011, it focuses on creating applications for managing healthcare data, particularly through its flagship product, Medicapp EHR. This mobile application allows healthcare professionals to efficiently manage patient health records, documents, photos, and notes. By providing tools for the creation, classification, and communication of patient records, Medicapp Connect aims to streamline recordkeeping for healthcare providers, including physiotherapists, enhancing their ability to deliver care effectively.

Ensweet is a telemedicine platform specializing in telerehabilitation services aimed at enhancing patient accessibility to rehabilitation care. The company provides a range of equipment, including heart rate sensors and physical activity tools, allowing patients to engage in exercise regardless of their circumstances. This innovative approach ensures that rehabilitation is accessible to all, promoting healthier lifestyles and improved recovery outcomes for individuals in need of rehabilitation services.